NCT06730308 Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
| NCT ID | NCT06730308 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Sun Yat-sen University |
| Condition | Thymoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-11-20 |
| Primary Completion | 2028-11-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 45 participants in total. It began in 2024-11-20 with a primary completion date of 2028-11-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed type AB or B1-3 thymoma. * Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors). * Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area. * Between the ages of 18 and 70 years, regardless of sex. * Eastern Cooperative Oncology Group performance status of 0 or 1. * No prior chest radiation. * Adequate organ Functions. * Written informed consent obtained. Exclusion Criteria: * Contraindications to Methylprednisolone. * History of or Concurrent Malignancy. * Active infection, myocardial infarction within the last 6 months or symptomatic heart disease. * Pregnant or Lactating Women. * Bleeding Disorders. * Recent Participation in Other Clinical Trials. * Drug Abuse or Severe Alcoholism. * Uncontrolled Seizures or Mental Disorders. * Severe Allergies or Specific Sensitivities.
Frequently Asked Questions
Who can join the NCT06730308 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Thymoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06730308 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06730308 currently recruiting?
Yes, NCT06730308 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sun Yat-sen University to inquire about joining.
Where is the NCT06730308 trial being conducted?
This trial is being conducted at Guanzhou, China.
Who is sponsoring the NCT06730308 clinical trial?
NCT06730308 is sponsored by Sun Yat-sen University. The trial plans to enroll 45 participants.